CD279(PD-1)-muIg Biotinylated

Molecular Structure:  A soluble fusion protein consisting of the extracellular (137aa) domain of human CD279(PD-1):  (25)ldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspspr(161)

Linking amino acids: sagtr

murine IgG2a Fc +hinge: (133 aa) eprgptikpcppckcpapnllggpsvfifppkikdvlmislspivtcvvvdvseddpdvqiswfvnnvevhtaqtqthredynstlrvvsalpiqhqdwmsgkefkckvnnkdlpapiertiskpkgsvrapqvyvlpppeeemtkkqvtltcmvtdfmpediyvewtnngktelnykntepvldsdgsyfmysklrvekknwvernsyscsvvheglhnhhttksfsrtpgk 

In SDS-PAGE, this protein runs at 52 kd under native, and 27 kd under reducing conditions.  

Data suggest that the murine Ig Fc proximal portion of this construct may be prone to cleavage.

Transfectant Cell Line:       CHO                                        

INFORMATION Human CD279 (PD-1, Programmed death 1) is a 55 kd Ig superfamily member  with similarity to CD28 and CD152(CTLA-4).    It is expressed on activated T and B and myeloid cells, and engagement by its ligands PD-L1 (CD274, B7-H1) or PD-L2 (B7-DC) can inhibit proliferation and cytokine expression.  In mice blockade of PD-1 ligand interaction has been used to augment T cell anti cancer responses (1,2,3). 

Recombinant CD279 -muIg binds to recombinant CD274 and CD273 in EIA and cell surface CD273 on moDC in FACS. It is recognized by anti-CD279 mAb (cat #279-030; clone ANC4H6) in EIA.

References:  .  1) MA Curran, Allison JP, et al. (2010) PNAS 107(9): 4275-80.  2) Mangsbo SM, TH Totterman, et al. (2010) J Immunotherapy 33(3):225. 3) Hirano F, L Chen, et al. (2005) Canc Res 65: 1089.